Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 50 citations in OpenAlex.

1. Reslizumab as add-on therapy in patients with refractory asthma.BMJ open respiratory research · 2020
   Trial
2. Eosinophil-Driven vs. Eosinophil-Associated Severe Asthma: Practical Implications for Target Treatment.International journal of molecular sciences · 2025
   Review
3. Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases.Biomedicines · 2024
   Review
4. Cellular activation pathways and interaction networks in vascularized composite allotransplantation.Frontiers in immunology · 2023
   Review
5. Targetable pathogenic mechanisms in nasal polyposis.International forum of allergy & rhinology · 2021
   Review
6. Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice.Chest · 2021
   Article
7. Real-life experience with benralizumab during 6 months.BMC pulmonary medicine · 2020
   Article
8. In patients with severe asthma with eosinophilia in reslizumab clinical trials, high peripheral blood eosinophil levels are associated with low FEVAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2020
   Article
9. CARD9Nature immunology · 2018
   Article
10. Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives.Patient related outcome measures · 2018
    Review
11. Role of biologics in severe eosinophilic asthma - focus on reslizumab.Therapeutics and clinical risk management · 2016
    Review
12. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.mAbs · 2016
    Article
13. Update on reslizumab for eosinophilic asthma.Expert opinion on biological therapy · 2015
    Review
14. Changing roles of eosinophils in health and disease.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2014
    Review
15. Omalizumab for severe asthma: efficacy beyond the atopic patient?Drugs · 2014
    Review
16. Activated mouse eosinophils protect against lethal respiratory virus infection.Blood · 2014
    Article
17. Ganoderma formosanum polysaccharides attenuate Th2 inflammation and airway hyperresponsiveness in a murine model of allergic asthma.SpringerPlus · 2014
    Article
18. Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.Clinical reviews in allergy & immunology · 2013
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as